000099278 001__ 99278
000099278 005__ 20230519145435.0
000099278 0247_ $$2doi$$a10.1371/journal.pone.0245610
000099278 0248_ $$2sideral$$a122639
000099278 037__ $$aART-2021-122639
000099278 041__ $$aeng
000099278 100__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000099278 245__ $$aEffect of patient and treatment factors on persistence with antihypertensive treatment: A population-based study
000099278 260__ $$c2021
000099278 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099278 5203_ $$aPurpose: To analyze patterns of antihypertensive drug use among new users in a Southern European population, and identify patient- and treatment-related factors that influence persistence.
Methods: This is a retrospective observational study of new antihypertensive drug users aged ≥40 years in Aragón, Spain. Information on antihypertensive drugs (2014-2016) prescribed and dispensed at pharmacies via the public health system were collected from a regional electronic population-based pharmacy database. Persistence was assessed using the gap method. Kaplan-Meier and Cox regression analyses were conducted to analyze patterns of use and factors that influence persistence.
Results: The 25,582 new antihypertensive drug users in Aragón during the study period were prescribed antihypertensive drugs in monotherapy (73.3%), fixed combination (13.9%), free combination (9.1%), or other (3.7%). One in five received antihypertensive drugs within 15 days of the prescription date, but not after. During the first year of follow-up, 38.6% of the study population remained persistent. The likelihood of treatment discontinuation was higher for participants who were male, aged ≥80 years, and received an antihypertensive drug in monotherapy compared with fixed combination.
Conclusion: Overall persistence with antihypertensive therapy was poor, and was influenced by the sex, age and type of therapy. Fixed combinations appear to be a good choice for initial therapy, especially in patients with a higher risk of discontinuation. Nonetheless, adverse drug effects and the patient's preferences and clinical profile should be taken into account.
000099278 536__ $$9info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-17R
000099278 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099278 590__ $$a3.752$$b2021
000099278 592__ $$a0.852$$b2021
000099278 591__ $$aMULTIDISCIPLINARY SCIENCES$$b29 / 74 = 0.392$$c2021$$dQ2$$eT2
000099278 593__ $$aMultidisciplinary$$c2021$$dQ1
000099278 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099278 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza
000099278 700__ $$aFeja, Cristina
000099278 700__ $$aLallana, MªJesús
000099278 700__ $$aArmesto, Javier
000099278 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, MªJosé$$uUniversidad de Zaragoza
000099278 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000099278 773__ $$g16, 1 (2021), e0245610 [13 pp.]$$pPLoS One$$tPLoS ONE$$x1932-6203
000099278 8564_ $$s1149201$$uhttps://zaguan.unizar.es/record/99278/files/texto_completo.pdf$$yVersión publicada
000099278 8564_ $$s2200046$$uhttps://zaguan.unizar.es/record/99278/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099278 909CO $$ooai:zaguan.unizar.es:99278$$particulos$$pdriver
000099278 951__ $$a2023-05-18-14:23:04
000099278 980__ $$aARTICLE